Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in advanced solid tumors with FGF/FGFR alterations
NCT06022289Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in solid tumor, sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Progression-free Survival 2 / Progression-free Survival 1 at 1 year. Status: unknown.
02
Drugs
pemigatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06022289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022289.